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Background and purposes: To determine the prevalence of SLC2A1 mutations in
children with early-onset absence epilepsy (EOAE) and to investigate whether there
were diﬀerences in demographic and electroclinical data between patients who
became seizure-free with anti-epileptic drug (AED) monotherapy (group I) and
those who needed add-on treatment of a second AED (group II).
Methods: We reviewed children with EOAE attended diﬀerent Italian epilepsy cen-
ters. All participants had onset of absence seizures within the ﬁrst 3 years of life but
otherwise conformed to a strict deﬁnition of childhood absence epilepsy. Mutation
analysis of SLC2A1 was performed in each patient.
Results: Eighty-four children (57 in group I, 27 in group II) fulﬁlled the inclusion
criteria. No mutation in SLC2A1 was found. There were no statistical diﬀerences
between the two groups with regard to F/M ratio, age at onset of EOAE, early his-
tory of febrile seizures, ﬁrst-degree family history for genetic generalized epilepsy,
duration of AED therapy at 3 years after enrollment, use of AEDs at 3 years, failed
withdrawals at 3 years, terminal remission of EOAE at 3 years, and 6-month fol-
low-up EEG data. Mean duration of seizures/active epilepsy was signiﬁcantly
shorter in group I than in group II (P = 0.008).
Conclusions: We demonstrate that in a large series of children with rigorous diag-
nosis of EOAE, no mutations in SLC2A1 gene are detected. Except for duration of
seizures/active epilepsy, no signiﬁcant diﬀerences in demographic and electroclinical
aspects are observed between children with EOAE who responded well to AED
monotherapy and those who became seizure-free with add-on treatment of a second
AED.
Introduction
Childhood absence epilepsy (CAE) is a well-recog-
nized prototype of genetic generalized epilepsy
(GGE) with typical absence seizures (TAS), which
manifest with transient impairment of consciousness
associated with bilateral, regular, symmetric and
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generalized 3–4 Hz spike-waves on electroencephalo-
gram (EEG) [1]. According to the strict criteria pro-
posed by Panayiotopoulos, the onset of CAE must be
limited between 4 and 10 years of age with a peak at 5
–7 years [2]. Although lower age at onset compatible
with CAE is uncertain, clinical series of children with
TAS starting from a few months to 3 years of age
have been reported [3–5]. It is possible that early-onset
absence epilepsy (EOAE) is a distinct syndrome within
the spectrum of GGE showing electroclinical features,
response to therapy and prognosis, similar but not
identical to CAE. In the majority of cases, a good
anti-epileptic drug (AED) response with rapid disap-
pearance of seizures is obtained with monotherapy,
while in some children, add-on of another AED is
needed [4,5].
Recently, mutations in SLC2A1 gene leading to
reduced function of glucose transporter type 1
(GLUT-1), the molecule transporting glucose across
the blood–brain barrier, have been found in over 10%
of subjects with absences starting before 4 years of
age [6].
The purpose of this retrospective multicenter study
was to determine the prevalence of mutations in
SLC2A1 gene in children presenting with our strict
criteria for EOAE, rather than the previously used
broad criteria, and to investigate whether demo-
graphic (age at onset, early history of febrile seizures,
ﬁrst-degree family history for GGE) and electroclini-
cal features (treatment outcomes, 6-month follow-up
EEG data) were diﬀerent between patients who
responded to monotherapy and patients who needed
add-on therapy.
Methods
Patients and study design
We reviewed retrospectively the medical records of all
children with a strict diagnosis of EOAE attended
sixteen diﬀerent Italian epilepsy centers between 2001
and 2009 for at least 3 years. The study was approved
by the Ethics Committee of each institution. All
parents gave informed consent.
Inclusion criteria were as follows: (i) onset within
the ﬁrst 3 years of age; (ii) daily TAS accompanied by
bilateral, regular, symmetric and generalized 3–4 Hz
spike-waves with normal background on EEG; (iii) nor-
mal development and neurologic examination at onset;
(iv) no brain imaging abnormalities. Patients were not
eligible if there were: (i) other seizures as generalized
tonic-clonic seizures or myoclonic jerks before or
during the absences; (ii) eyelid or perioral myoc-
lonia, rhythmic massive limb jerking, and single or
arrhythmic myoclonic jerk of the head, trunk, or
limbs; (iii) no impairment of consciousness during the
3–4 Hz spike-waves discharges; (iv) photic and other
sensory precipitation of clinical seizures. These strict
criteria utilized a diﬀerent deﬁnition of EOAE to that
used in the context of GLUT-1 deﬁciency syndrome,
which included patients with onset of absences before
4 years of age, no evidence of a secondary cause
for epilepsy, generalized spike-waves on EEG, and
absence of atonic/tonic seizures [6].
We subdivided all patients into two categories
according to their AED response: group I (children
who responded well to the ﬁrst AED monotherapy
and became seizure-free) and group II (children who
became clinically seizure-free with add-on treatment
of a second AED, after the maximum-tolerated dose
of the ﬁrst AED had been achieved).
The two groups were compared with regard to the
following aspects: sex; age at onset of EOAE; occur-
rence of febrile seizures (FS) prior to EOAE; ﬁrst-
degree family history of GGE; duration of seizures/
active epilepsy; duration of AED therapy at 3 years
after enrollment; number of patients receiving AEDs
at 3 years; number of failed withdrawals at 3 years;
terminal remission of EOAE at 3 years (deﬁned as the
time from the last seizure to 3-year follow-up); EEG
data collected after 6 months from the EOAE onset;
and occurrence of mutations in SLC2A1 gene (muta-
tion analysis of SLC2A1 was performed on genomic
DNA by direct sequencing).
Statistical analysis
Statistical analysis was conducted using SPSS Version
17.0 (SPSS Inc, Chicago, IL, USA). The results are
expressed as means (SD) for continuous variables and
as percentages for categorical variables. Comparisons
of continuous data were performed with Student’s
t-test, and those of categorical data with the v2 test.
Statistical signiﬁcant was deﬁned as a P-value <0.05.
Results
Eighty-four children (F/M ratio: 35/49) fulﬁlled the
inclusion criteria. Mean age at onset was
25.5 ± 7.9 months. Twenty patients (23.8%) had a
history of FS before the onset of TAS, and 29
(34.5%) had a ﬁrst-degree family history of GGE. All
children were treated with AEDs and after a follow-
up period of 3 years, seizures were controlled in each
patient with 59 children (70.2%) still on therapy. Mean
terminal remission at 3 years was 2.7 ± 0.3 years.
Mutations in SLC2A1 were not identiﬁed in any
subject.
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Group I included 57 patients (67.9%) and group II 27
patients (32.1%). In group I, 41 children (71.9%) were
treated with valproate (mean dose, 27.9 ± 7.1 mg/kg/day),
10 (17.5%) with ethosuximide (mean dose, 25.1 ± 3.5 mg/
kg/day) and 6 (10.6%) with lamotrigine (mean dose,
3.2 ± 1.5 mg/kg/day). In group II, 16 patients (59.3%)
received valproate (mean dose, 24.5 ± 8.1 mg/kg/
day) + ethosuximide (mean dose, 21.8 ± 6.1 mg/kg/day), 8
(29.6%) valproate (mean dose, 27.9 ± 5.4 mg/kg/
day) + lamotrigine (mean dose, 3.8 ± 1.3 mg/kg/day), and
3 (11.1%) valproate (mean dose, 24.1 ± 7.3 mg/kg/
day) + levetiracetam (mean dose, 27.2 ± 5.3 mg/kg/day).
The mean time between the start of the ﬁrst and second
AED was 1.8 ± 0.7 months.
No signiﬁcant diﬀerences in demographic and elec-
troclinical variables, except for mean duration of
seizures/active epilepsy (P = 0.008), were observed
between the two groups (Table 1).
Discussion
This study demonstrates that in a large series of chil-
dren with rigorous diagnosis of EOAE, no mutations
in SLC2A1 gene are detected. SLC2A1 mutations are
not found in EOAE per se but are part of the under-
lying condition (GLUT-1 deﬁciency syndrome). Appli-
cation of our strict criteria leads to a group of
children with homogeneous disease characteristics and
prognosis. Reasonably, in patients with newly sus-
pected EOAE who are in accordance with these
proposed criteria, it is advisable not to assess the
SLC2A1 gene mutations.
All children of this study were treated with AEDs
and became seizure-free with an elevated terminal
remission of epilepsy at 3 years (2.7 ± 0.3 years). Such
a good response was mainly obtained in monotherapy
(67.9%) with valproate, ethosuximide, or lamotrigine.
Nevertheless, in nearly one-third of cases, seizures ces-
sation could be achieved only with a combination of
two AEDs. These two categories of patients showed
similar demographic and electroclinical aspects, except
for duration of seizures/active epilepsy, which
appeared signiﬁcantly shorter in children treated with
AED monotherapy than in those who became seizure-
free with add-on therapy of a second AED, after the
maximum-tolerated dose of the ﬁrst AED had been
achieved. These ﬁndings are in line to those reported
in children with CAE [7].
Although this is not an epidemiological study, the
large number of patients with EOAE observed over
a 7-year period could lead to reconsider the real
prevalence of this epilepsy. In a previous study, we
had observed that children with TAS starting within
the ﬁrst 3 years of life represented about 3.5%
of all subjects with TAS observed in a 15-year
period [4].
Among our patients, there was a slight male pre-
ponderance, in contrast to the pattern generally seen
in CAE [7]. In our series, 34.5% had a ﬁrst-degree
family history for GGE, and 23.8% had a history of
FS before the onset of TAS. These high percentages
may suggest the possibility of a speciﬁc epileptic
syndrome with putative familiar inheritance.
In conclusion, our study suggests that children
who conform to our strict diagnostic criteria for
EOAE do not have a high risk of SLC2A1 gene
mutations. This is signiﬁcantly diﬀerent to previous
reports using a broad deﬁnition of EOAE. Our
patients present a homogeneous prognosis with com-
plete absence seizures control on AED treatment
and epilepsy remission similar to those reported in
CAE. These ﬁndings also demonstrated that, as long
as the other parts of CAE deﬁnition are fulﬁlled,
age of onset has little eﬀect on prognosis; therefore,
strict-deﬁnition EOAE may be included as a part
of CAE.
Table 1 Comparison of demographic and electroclinical features
between the two groups
Group I
(n = 57)
Group II
(n = 27) P-value
F/M ratio 24/33 11/16 0.906
Age at onset
(months)
24.8 ± 7.6 26.7 ± 8.4 0.193
Personal history of
febrile seizures (%)
14 (24.6) 6 (22.2) 0.814
First-degree relatives
with GGE (%)
19 (33.3) 10 (37.0) 0.739
Duration of
seizures/active epilepsy
(months)
2.0 ± 0.6 2.4 ± 0.5 0.008
Duration of AED
therapy at 3-year
follow-up (years)
2.5 ± 0.7 2.8 ± 0.4 0.138
Patients using AED at
3-year follow-up (%)
39 (68.4) 20 (74.1) 0.597
Failed withdrawals during
3-year follow-up (%)
6/18 (33.3) 2/7 (28.6) 0.649
Terminal remission at
3-year follow-up (years)
2.8 ± 0.4 2.6 ± 0.3 0.077
6-month follow-up EEG data
Normal (%) 43 (75.4) 21 (77.8) 0.814
Generalized 3–4 Hz
spike-wave complexes (%)
7 (12.3) 4 (14.8) 0.748
Generalized epileptiform
discharges (%)
4 (7.0) 1 (3.7) 0.549
Focal epileptiform
discharges (%)
3 (5.7) 1 (3.7) 0.754
SLC2A1 mutations (%) 0 0 –
AED, anti-epileptic drug; GGE, genetic generalized epilepsy.
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